Revenue Performance - Revenue decreased 3% in Q1 2025 to $1,041 million compared to $1,076 million in Q1 2024, primarily due to a decrease in service and other revenue driven by the Spin-Off of GRAIL[130] - Total revenue for Q1 2025 was $1,041 million, a decrease of 3.2% compared to $1,076 million in Q1 2024[18] - Core Illumina total product revenue decreased by 3% to $880 million in Q1 2025 from $883 million in Q1 2024[134] - Product revenue increased slightly to $880 million, up from $876 million year-over-year[18] - Revenue from the Greater China region, including China, Taiwan, and Hong Kong, was $308 million in 2024, indicating significant exposure to regulatory risks in that market[167] Profitability and Income - Net income in Q1 2025 was $131 million, a significant increase from a net loss of $126 million in Q1 2024[142] - Income from operations was $164 million in Q1 2025 compared to a loss of $(111) million in Q1 2024, primarily due to a decrease in operating expenses of $259 million[131] - Net income for Q1 2025 was $131 million, compared to a net loss of $126 million in Q1 2024[26] - Gross profit for the quarter was $683 million, compared to $667 million in the same period last year, reflecting a gross margin increase[18] Expenses and Cost Management - Total consolidated operating expense decreased by $259 million, or 33%, from Q1 2024 to Q1 2025, totaling $519 million[138] - Core Illumina's SG&A expense decreased by $69 million, or 21%, in Q1 2025, mainly due to a favorable impact from contingent consideration liability related to GRAIL[139] - Research and development expenses were $252 million, down from $339 million in Q1 2024, reflecting cost management efforts[18] - The company implemented a $100 million cost reduction program in Q1 2025 to mitigate expected revenue declines, particularly from the Greater China business[128] Cash and Investments - Cash, cash equivalents, and short-term investments totaled $1,237 million at the end of Q1 2025, with approximately $432 million held by foreign subsidiaries[131] - As of March 30, 2025, the company had $1,113 million in cash and cash equivalents, with $432 million held by foreign subsidiaries[147] - The company anticipates that current cash, cash equivalents, and short-term investments are sufficient to fund near-term capital and operating needs for at least the next 12 months[153] Tax and Regulatory Matters - The effective tax rate was 27.9% in Q1 2025 compared to (15.3)% in Q1 2024, primarily due to the impact of research and development expense capitalization for tax purposes[131] - The company faces various risks, including potential penalties from regulatory authorities in China, which could materially impact revenue and operations[166] - The company was added to China's List of Unreliable Entities on February 4, 2025, which may lead to fines or restrictions on business operations in China, potentially adversely affecting revenue and results[166] Shareholder Actions and Stock Performance - In Q1 2025, the company repurchased $200 million of its common stock as part of its share repurchase program[158] - The company repurchased 1.728 million shares at a total cost of $201 million during Q1 2025, with $1.2 billion remaining available for repurchase as of March 30, 2025[72][71] - In August 2024, the Board of Directors authorized a new share repurchase program to buy back up to $1.5 billion of outstanding common stock, with 1,728 thousand shares repurchased at an average price of $115.74 per share during Q1 2025[168] GRAIL Spin-Off and Related Developments - The Spin-Off of GRAIL on June 24, 2024, resulted in Illumina stockholders receiving one share of GRAIL common stock for every six shares of Illumina common stock held[124] - The company completed the separation of GRAIL into a separate publicly traded company, distributing approximately 85.5% of GRAIL's outstanding common stock to Illumina stockholders[88] - The U.S. Federal Trade Commission dismissed the administrative complaint related to the company following the completion of the Spin-Off[91] Market and Operational Risks - The estimated cost impact of tariffs enacted in April 2025 is approximately $85 million, primarily related to importation from the manufacturing facility in Singapore[129] - The company continues to focus on operational excellence and cost reduction initiatives to enhance growth and expand operating margins[131] - The company is subject to uncertainties regarding the impact of tariffs announced by the U.S. Government and other countries, which could affect financial performance[10]

Q1 2025 Earnings Presentation May 8, 2025 © 2025 Illumina, Inc. All rights reserved. Cautionary Notes This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our abi ...

Financial Data and Key Metrics Changes - First quarter revenue was $1,040 million, down 1.4% year over year, with constant currency revenue roughly flat [20][19] - Non-GAAP EPS was $0.97, at the upper end of guidance [19][27] - Non-GAAP gross margin increased by 30 basis points year over year to 67.4% [25] - Non-GAAP operating margin was 20.4% in Q1 [27] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $696 million, growing approximately 1% year over year [20] - Sequencing instruments revenue was approximately flat year over year at $109 million [23] - Sequencing service and other revenue was down approximately 5% year over year to $142 million [24] Market Data and Key Metrics Changes - Clinical business showed mid single-digit growth, while research business was down in the high mid to high single-digit range [50][49] - Approximately 68% of high throughput gigabases shipped were on the NovaSeq X Series [22] - Over 50% of clinical volumes are now on the NovaSeq X Series [22] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and 500 basis points margin expansion by 2027, excluding Greater China [10] - A $100 million cost reduction program was initiated to address challenges from China and research funding uncertainty [12] - The company is focusing on advancing the Multiomics ecosystem and has a strong innovation pipeline [9][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges but expressed confidence in the company's resilience and growth potential [7][10] - The company is revising guidance to reflect headwinds from China and research funding uncertainties [11][29] - Management emphasized that the challenges are transitory and will not define long-term success [10] Other Important Information - The company is engaging with regulatory authorities in China for potential solutions to support a sustainable long-term presence [11] - The impact of new tariffs is estimated to be approximately $85 million for 2025, with actions being taken to mitigate this [35][36] Q&A Session Summary Question: What is the outlook for revenue growth and margin expansion? - Management believes that revenue growth will rebound and margins will expand above 25% in the future, despite current challenges [42] Question: What are the clinical and research revenue growth rates? - Clinical revenue grew mid single digits, while research revenue declined in the high mid to high single-digit range [50][49] Question: How is the company managing risks related to China? - The company has taken actions to offset potential risks from China, including a $100 million cost reduction program [46] Question: How are tariffs impacting demand? - No significant change in customer behavior was observed in Q1 due to tariffs, but future impacts are anticipated [68][70] Question: What are the assumptions behind the revenue guidance? - The guidance reflects a 15% decline in research revenue, offset by stronger clinical performance [76][78]

Financial Data and Key Metrics Changes - Q1 2025 revenue was $1,040 million, down 1.4% year over year, with constant currency revenue roughly flat [19][30] - Non-GAAP EPS was $0.97, at the high end of guidance [18][27] - Non-GAAP gross margin increased by 30 basis points year over year to 67.4% [24] - Non-GAAP operating margin was 20.4% in Q1 [27] - Cash flow from operations was $240 million, with free cash flow at $208 million [28] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $696 million, growing approximately 1% year over year [19] - Sequencing instruments revenue was approximately flat at $109 million [22] - Sequencing service and other revenue decreased by approximately 5% year over year to $142 million [23] Market Data and Key Metrics Changes - Clinical business consumables grew mid-single digits, while research consumables were down in the high mid to high single-digit range [49] - The Greater China region is expected to contribute only $165 million to $185 million in full-year revenue, significantly down from previous levels [30][32] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and 500 basis points margin expansion by 2027, excluding Greater China [8][10] - A $100 million cost reduction program was initiated to address challenges in China and the U.S. funding environment [11][25] - The company is focused on advancing its Multiomics ecosystem and has several new product launches planned for 2025 and 2026 [13][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges but emphasized the resilience of the business and strong sequencing activity [6][44] - The company is actively engaging with regulatory authorities in China to find long-term solutions [10][32] - Management expressed confidence in the long-term growth trajectory despite current headwinds [9][39] Other Important Information - The company is revising its guidance to reflect geopolitical impacts, particularly in China [29] - The estimated gross cost of tariffs for 2025 is approximately $85 million, impacting margins [34][35] Q&A Session Summary Question: What is the outlook for revenue growth and margins? - Management believes revenue growth will rebound and margins will expand above 25% in the future, with a focus on cost control [41][42] Question: What are the growth rates for clinical and research segments? - Clinical revenue grew mid-single digits, while research revenue is expected to decline in the mid-double digits for the remainder of the year [49][50] Question: How are tariffs affecting demand? - No significant change in customer behavior was observed in Q1 due to tariffs, but future impacts are anticipated [66][68] Question: What is the impact of China on future revenue? - The company expects continued revenue decline from China, with proactive measures in place to mitigate risks [96]

Investors: Brian Blanchett +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 | | | | GAAP | | | | Non-GAAP (a) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Dollars in millions, except per share amounts | | Q1 2025 | | Q1 2024 | | Q1 2025 | | Q1 2024 | | Revenue (b) | $ | 1,041 | $ | 1,056 | $ | 1,041 | $ | 1,056 | | Gross margin (c) | | 65.6 % | | 65.7 % | | 67.4 % | | 67.1 % | | Research and de ...

Core Insights - Analysts forecast Illumina (ILMN) to report quarterly earnings of $0.96 per share, reflecting a year-over-year increase of 966.7% [1] - Expected revenues are projected at $1.04 billion, indicating a decline of 3.5% compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 0.6% in the past 30 days [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Breakdown - Analysts expect 'Revenue- Product revenue- Consumable' to be $763.09 million, showing a year-over-year change of +0.1% [5] - The estimate for 'Revenue- Service and other revenue' is $170.12 million, suggesting a decline of 14.9% year over year [5] - 'Revenue- Product revenue' is predicted to reach $872.04 million, indicating a decrease of 0.5% [5] Core Revenue Metrics - 'Revenues- Core Illumina- Service and other revenue' is expected to be $175.08 million, reflecting a year-over-year increase of 1.2% [6] - 'Revenues- Core Illumina- Total product revenue' is projected at $869.69 million, suggesting a decline of 1.5% year over year [6] Instrument and Consumable Revenue - 'Revenue- Product revenue- Instruments' is likely to be $108.95 million, indicating a change of -4.4% from the prior-year quarter [7] - 'Revenues- Core Illumina- Consumables' is expected to reach $748.87 million, reflecting a decrease of 2.6% [7] Sequencing Revenue Estimates - 'Revenue- Sequencing- Instruments' is projected at $108.51 million, indicating a change of -1.4% from the year-ago quarter [8] - 'Revenue- Sequencing- Consumables' is expected to be $679.85 million, suggesting a decline of 2.6% year over year [8] Microarrays Revenue Forecast - 'Revenue- Microarrays- Instruments' is estimated to reach $3.61 million, indicating a change of -9.9% from the prior-year quarter [9] - 'Revenue- Microarrays- Consumables' is projected at $74.59 million, reflecting a year-over-year change of +5.1% [9] - Overall, 'Revenue- Core Illumina' is expected to be $1.03 billion, indicating a decline of 2.1% year over year [9] Stock Performance - Illumina shares have returned +5% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [9] - With a Zacks Rank 3 (Hold), ILMN is expected to mirror the overall market performance in the near future [10]

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapiesDataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapiesSAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially av ...

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering. In terms of deals related to genetic target validation, there have been 14,172 deals totaling US$11.4 billion. The United States has been a major player in this space, with a significant Grants deal worth $7.8 billion. The highest deal volume was seen in 2023 with 3,569 deals, while the highest deal value was recorded in 2020 at $4.1 billion ...

导读： 近期，关税战愈演愈烈，在此背景下，我们特别盘点美国十家科学仪器企业在华的发展布局，以期洞察未来趋势。 他还着重表示，珀金埃尔默太仓工厂扩建项目已完成，新的现代化生产设施和运营平台将在现有的太仓基地附近投产，面积扩大近四倍，并将 逐步实现全品类产线转移。这将进一步提升公司在中国市场的生产和运营规模，更好地服务中国客户。珀金埃尔默将持续关注中国市场与客户 需求的变化，不断推出适应中国市场的产品和解决方案，为中国客户提供创新技术和专业服务。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2 0 2 5年2月2 8日，胡润研究院发布《2 0 2 4在中国的美国企业特别报告》，报告共收集了7 0家标普5 0 0成分股美国企业的数据，这些企业均披露 了其在中国市场的营收数据。 样本企业在全球市场的收入总额超过2 . 5万亿美元，相当于美国2 0 2 3年GDP总和的9%。报告中不仅提及了苹 果、特斯拉、沃尔玛等知名企业，还特别关注了珀金埃尔默、r e v v it y等科学仪器领域的美国品牌。 回顾历史，自上世纪8 0年代前后，珀金埃 ...

来源丨 投中网 什么是青年？可以用数据说话。联合国将青年定义为 15-24 岁，世界卫生组织则将年龄范围扩展到 15-44 岁。可以用古语说话。"后生可畏"的箴言 揭示着东方文明对青春力量的敬畏。也可以用概念说话。文艺复兴后，"青年"作为独立概念出现，经过五四运动后在中国普及，成为社会变革的象征。 对于投资，青年又意味着始终处于"成为"（ becoming ）的状态。在湍急的时代浪潮中，青年投资人要不断寻找自身的定位，校准自己的价值观，整 合各种不同的看待世界的方法和模型，形成一套自己的认知体系，当然，最重要的，投资人要与时代共振。 生命力是主体的一种经验和感受，是意识和行动之间的间隔。而投资正是社会生命力的象征。我们希望青年投资人能活出饱满的生命力。既能躬身入 局，中流击水，也能及时抽身，理清时代的脉络。既能理解宏观经济趋势，深入分析行业来龙去脉，更需在信息过载时筛选出有效信号，在快速变化的 市场中保持新鲜的眼光和敏锐的洞察力。 投资人要与时代共振。 | 5 | 邓到 | 陆石投资 | 北京、天津、成都 | 爱思达航天 天兵科技 | | --- | --- | --- | --- | --- | | | | ...